Clinical trials: Tumor of Bone
Leukemia
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00093639
- Testing
- everolimus, imatinib mesylate
- Where
- United States
- Sponsor
- Novartis Pharmaceuticals
AML, MDS
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
- Trial name
- NCT04017546
- Testing
- CYC065, Venetoclax
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Breast Cancer, Metastatic Bone Disease
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
This is a 4-week study to examine the effects of a new experimental medication on women with breast cancer and established bone metastases. This study will enroll approximately 45 women.
- Trial name
- NCT00399802
- Testing
- ZA, Odanacatib
- Volunteers
- 43 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- HATCY (NCT02999854)
- Testing
- ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor
- Where
- 42 sites in United States, Belgium and 11 more
- Volunteers
- 63 people
- Sponsor
- Kiadis Pharma
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Study CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and…
- Trial name
- NCT02641002
- Testing
- CC-90002
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Celgene
Gorlin Syndrome
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.
- Trial name
- NCT06050122
- Testing
- Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 113 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Osteosarcoma Metastatic
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma…
- Trial name
- NCT00102531
- Testing
- Cisplatin liposomal
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Insmed Incorporated
Metastatic Solid Tumors
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases
- Trial name
- NCT07249892
- Testing
- BPR-6023021 for injection
- Where
- China
- Volunteers
- 195 people
- Sponsor
- Chengdu Syncor Pharmaceutical Co., Ltd.
Thrombocytopenia, Hematologic Malignancy
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate…
- Conditions
- Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders
- Trial name
- NCT04631211
- Testing
- Thrombosomes, Liquid Stored Platelets (LSP)
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 21 people
- Sponsor
- Cellphire Therapeutics, Inc.
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.
This single arm study will assess the efficacy and safety of loading doses of intravenous Bondronat in patients with breast cancer and malignant bone disease experiencing moderate to severe bone pain.
- Trial name
- NCT00502736
- Testing
- ibandronate [Bondronat]
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 13 people
- Sponsor
- Hoffmann-La Roche
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory…
- Trial name
- NCT03922100
- Testing
- NMS-03592088
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 63 people
- Sponsor
- Nerviano Medical Sciences
Biliary Tract Cancer
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with…
- Trial name
- FOENIX-BTC (NCT07710885)
- Testing
- Futibatinib, Zimberelimab, Durvalumab
- Where
- 21 sites in Australia, Japan and 2 more
- Volunteers
- 784 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Breast Cancer, Osteoporosis
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
- Trial name
- NCT00767585
- Where
- Slovenia
- Volunteers
- 560 people
- Sponsor
- AstraZeneca
Essential Thrombocythemia
Anagrelide Retard in Essential Thrombocythemia
The purpose of this study is determine whether Anagrelide Retard is non-inferior to anagrelide immediate release form in treatment of essential thrombocythemia.
- Trial name
- TEAM-ET (NCT02076815)
- Testing
- Anagrelide retard, Thromboreductin
- Where
- 19 sites in Austria, Bulgaria and 3 more
- Volunteers
- 106 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Advanced or Refractory Leukemia, Myelodysplastic Syndromes
A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
The purpose of this study is to explore the safety, pharmacokinetic (what the body does to the medication), pharmacodynamic (what the medication does to the body), and activity of JNJ-26481585 in patients with advanced or…
- Trial name
- NCT00676728
- Testing
- JNJ-26481585
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Polycythemia Vera, Essential Thrombocythemia
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK)…
- Trial name
- NCT01998828
- Testing
- Momelotinib
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 39 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis, Post-Polycythemia Vera
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
- Trial name
- FREEDOM2 (NCT03952039)
- Testing
- FEDRATINIB, Best Available Therapy (BAT)
- Where
- 107 sites in Australia, Austria and 14 more
- Volunteers
- 202 people
- Sponsor
- Celgene
Giant Cell Tumor of Bone
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvageable or severe post-surgery…
- Trial name
- NCT05402865
- Testing
- Denosumab
- Where
- 3 sites in China
- Volunteers
- 301 people
- Sponsor
- Shanghai JMT-Bio Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.